Table 3.
PROs in UC patients categorized by ClinPRO2 and mucosal healing.
| UC Patients Categorized by ClinPRO2 and Mucosal Healing | p-Value | |||
|---|---|---|---|---|
| No Symptoms (n = 25) | Symptoms Present but MH (n = 15) | Symptoms Present and no MH (n = 50) | ||
| Median age, years (IQR) | 45 (32–63) | 49 (35–64) | 46 (31–54) | 0.38 |
| Male, n (%) | 9 (36%) | 7 (47%) | 25 (50%) | 0.24 |
| Extensive UC, n (%) | 14 (56%) | 11 (73%) | 30 (60%) | 0.78 |
| Current medication, n (%) | ||||
| 5-ASA use | 11 (44%) | 8 (53%) | 19 (38%) | 0.56 |
| Systemic corticosteroids | 1 (4%) | 2 (13%) | 13 (26%) | 0.06 |
| Immunosuppressive drugs | 7 (28%) | 6 (40%) | 12 (24%) | 0.48 |
| Biologic agents | 10 (40%) | 6 (40%) | 24 (48%) | 0.75 |
| Patient-reported outcomes, median (IQR) | ||||
| SIBDQ † | 62 (58–64) | 46 (33–56) * | 40.5 (31.8–51) * | < 0.01 |
| EQ5D3L † | 1 (0.827–1) | 0.827 (0.761–1) * | 0.816 (0.768–0.856) * | < 0.01 |
| WPAI ‡ | 0 (0–0) | 39.4 (16.9–71.7) * | 62.5 (28.0–85.8) * | < 0.01 |
| FACIT-F † | 47 (37–48.5) | 24 (19–45) * | 28.5 (18.8–40.3) * | < 0.01 |
| HADS-depression ‡ | 2 (1–3) | 6 (2–10) * | 4 (2–7.3) * | < 0.01 |
| HADS-anxiety ‡ | 4 (1–5) | 8 (4–10) * | 7 (4–10) * | < 0.01 |
* p < 0.05 when compared with no symptoms. SIBDQ: Short Inflammatory Bowel Disease Questionnaire, EQ5D3L: European Quality of Life 5-Dimensions 3-Level (time-trade-off), FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue, WPAI: Work Productivity and Activity Impairment questionnaire (% of overall work productivity impairment), HADS: Hospital Anxiety and Depression Scale. † Higher values for SIBDQ, EQ5D3L, and FACIT-F scores indicate good quality of life. ‡ Higher values for WPAI, HADS-depression, and HADS-anxiety scores indicate poor quality of life.